HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
A phase 2/3 trial testing HMPL-453 in biliary tract cancer, now recruiting.
Overview
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma is a phase 2/3 interventional study registered as NCT04353375, led by Hutchmed, and recruiting when checked on 2026-09-11. Official title: An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement. Planned enrolment is 235 participants (estimated). The study started in 2020-09-03 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Shares Hutchmed and the tag ctgov-ingest.
- TrialTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Shares Hutchmed and the tag ctgov-ingest.
- TrialA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Shares Hutchmed and the tag ctgov-ingest.
- TrialStudy of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-ingest.
- TrialD07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-ingest.
- TrialA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-ingest.
- TrialA Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-ingest.
- TrialA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-ingest.